Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808312 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT02808312 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 57 participants.
The verdict
NCT02808312, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
Interventions
- DRUG Cilofexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-07-13 |
| Est. Completion | 2018-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808312
The ClinicalTrials.gov registry entry for NCT02808312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cilofexor is the first listed.
NCT02808312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808312 about?
NCT02808312 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function". The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
What is the current status of trial NCT02808312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2016-07-13. Estimated completion is 2018-10-16.
What interventions are being tested in trial NCT02808312?
The interventions under investigation include: Cilofexor (DRUG).
Who is sponsoring clinical trial NCT02808312?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.